Skip to main content
Premium Trial:

Request an Annual Quote

NanoString Inks Loan Agreement for up to $45M

NEW YORK (GenomeWeb News) – NanoString Technologies said after the close of the market on Thursday it has reached a term loan agreement with Capital Royalty and certain of its affiliates to borrow up to $45 million.

Capital Royalty will initially provide NanoString with $30 million, of which $20 million will be borrowed up front to retire its existing loans with Oxford Finance and Silicon Valley Bank. Two years ago, NanoString entered into a $13 million senior secured term loan and a $2 million revolving line of credit with those entities.

Another $10 million will be borrowed within six months, and up to $15 million of additional funding will be available to NanoString through May 2015, the Seattle-based company said. The agreement has a six-year term.

Earlier this year, the company launched a follow-on public offering of its common stock that raised about $57 million.

At the JP Morgan Healthcare Conference in January, NanoString CEO Brad Gray said that driving adoption of the firm's recently launched Prosigna Breast Cancer Prognostic Gene Signature Assay would be a main focus of the company. Other priorities include development of a benchtop version of its nCounter Analysis system, as well as multianalyte and protein analysis assays, and efforts to secure reimbursement for the Prosigna test.

"Together with the capital we have raised through recent equity offerings, the agreement with Capital Royalty provides the funding we need to continue to pursue our business plan aggressively," Gray said in a statement. "The optional borrowing amounts provide added flexibility to fund other growth initiatives as opportunities arise."

The Scan

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.

Australian Survey Points to Public Support for Genetic Risk Disclosure in Relatives of At-Risk Individuals

A survey in the European Journal of Human Genetics suggests most adult Australians are in favor of finding out if a relative tests positive for a medically actionable genetic variant.

Study Links Evolution of Stony Coral Skeleton to Bicarbonate Transporter Gene

A PNAS paper focuses on a skeleton-related bicarbonate transporter gene introduced to stony coral ancestors by tandem duplication.

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.